233278-56-3

Basic information

• Product Name: 5,6,7,8-Tetrahydro-[1,2,4]triazolo[1,5-a]pyrazine
• Synonyms: 5,6,7,8-Tetrahydro-[1,2,4]triazolo[1,5-a]pyrazine;[1,2,4]Triazolo[1,5-a]pyrazine, 5,6,7,8-tetrahydro-;4H,5H,6H,7H-[1,2,4]triazolo[1,5-a]pyrazine
• CAS NO: 233278-56-3
• Molecular Formula: C₅H₈N₄
• Molecular Weight: 124.15
• Mol File: 233278-56-3.mol

Chemical Properties

• Boiling Point: 319.763°C at 760 mmHg
• Flash Point: 147.187°C
• Appearance: /
• Density: 1.539g/cm³
• Vapor Pressure: 0mmHg at 25°C
• Refractive Index: 1.773
• Storage Temp.: under inert gas (nitrogen or Argon) at 2–8 °C
• PKA: 6.05±0.20(Predicted)
• CAS DataBase Reference: 5,6,7,8-Tetrahydro-[1,2,4]triazolo[1,5-a]pyrazine(CAS DataBase Reference)
• NIST Chemistry Reference: 5,6,7,8-Tetrahydro-[1,2,4]triazolo[1,5-a]pyrazine(233278-56-3)
• EPA Substance Registry System: 5,6,7,8-Tetrahydro-[1,2,4]triazolo[1,5-a]pyrazine(233278-56-3)

Safety Data

• Hazardous Substances Data: 233278-56-3(Hazardous Substances Data)

Usage

Uses

Used in Pharmaceutical Industry:
5,6,7,8-Tetrahydro-[1,2,4]triazolo[1,5-a]pyrazine is used as a precursor for the synthesis of pharmaceutical compounds due to its unique chemical structure and potential biological activities.
Used in Central Nervous System Disorders Treatment:
5,6,7,8-Tetrahydro-[1,2,4]triazolo[1,5-a]pyrazine is used as an antagonist of the adenosine A1 receptor for the treatment of central nervous system disorders, potentially offering new therapeutic approaches for these conditions.
Used in Antioxidant Applications:
5,6,7,8-Tetrahydro-[1,2,4]triazolo[1,5-a]pyrazine is used as an antioxidant, which may help in protecting cells from oxidative damage and contribute to the development of new health-promoting products.
Used in Anti-infective Drug Development:
5,6,7,8-Tetrahydro-[1,2,4]triazolo[1,5-a]pyrazine is used as a potential anti-infective agent in the development of new antibiotics and antiviral drugs, addressing the need for novel treatments against resistant pathogens.
Used in Chemical Synthesis:
5,6,7,8-Tetrahydro-[1,2,4]triazolo[1,5-a]pyrazine is used as a building block for the synthesis of novel chemical entities, contributing to the advancement of chemical research and the creation of new compounds with various applications.

InChI:InChI=1/C5H8N4/c1-2-9-5(3-6-1)7-4-8-9/h4,6H,1-3H2

Upstream product

• 399-66-6 [1,2,4]triazolo[1,5-a]pyrazine 
• 1575612-94-0 (E)-N'-hydroxy-N-(pyrazin-2-yl)formimidamide 

Downstream Products

• 344778-62-7 5-[5,6-dihydro[1,2,4]triazolo[1,5-a]pyrazin-7(8H)-yl]-3-(2-fluorophenyl)-[1,2,3]triazolo[1,5-a]quinazoline 
• 914654-57-2 3-(5,6-dihydro[1,2,4]triazolo[1,5-a]pyrazin-7(8H)-ylmethyl)-2-phenylquinoline-4-carboxylic acid 
• 1460032-62-5 tert-butyl 4-[(4-chloro-2-[5H,6H,7H,8H-[1,2,4]triazolo[1,5-a]pyrazin-7-yl]phenyl)methyl]piperazine-1-carboxylate 

Relevant articles and documents

Design, synthesis, and structure-activity relationship studies of novel fused heterocycles-linked triazoles with good activity and water solubility

Triazoles with fused-heterocycle nuclei were designed and evaluated for their in vitro activity on the basis of the binding mode of albaconazole using molecular docking, along with SAR of antifungal triazoles. Tetrahydro-[1,2,4] triazolo[1,5-a]pyrazine and tetrahydro-thiazolo[5,4-c]pyridine nuclei were preferable to the other four fused-heterocycle nuclei investigated. Potent in vitro activity, broad spectrum and better water solubility were attained when triazoles containing nitrogen aromatic heterocycles were attached to these two nuclei. The most potent compounds 27aa and 45x, with low hERG inhibition and hepatocyte toxicity, both exhibited excellent activity against Candida, Cryptococcus, and Aspergillus spp., as well as selected fluconazole-resistant strains. A high water-soluble compound 58 (the disulfate salt of 45x) displayed unsatisfactory in vivo activity because of its poor PK profiles. Mice infected with C.alb. SC5314 and C.alb. 103 (fluconazole-resistant strain) and administered with 27aa displayed significantly improved survival rates. 27aa also showed favorable pharmacokinetic (PK) profiles.

SUBSTITUTED SULFONAMIDE DERIVATIVES

The invention relates to substituted sulfonamide derivatives of the general formula (I'); processes for their preparation, medicaments containing these compounds, and the use of substituted sulfonamide derivatives for the preparation of medicaments

SUBSTITUTED SULFONAMIDE COMPOUNDS

Substituted sulfonamide derivatives, a process for their preparation, pharmaceutical compositions containing these compounds, and to the use of substituted sulfonamide derivatives in the treatment or inhibition of pain and/or various disorders or disease states.

Design, synthesis, and biological evaluation of triazolopiperazine-based β-amino amides as potent, orally active dipeptidyl peptidase IV (DPP-4) inhibitors

Various β-amino amides containing triazolopiperazine heterocycles have been prepared and evaluated as potent, selective, orally active dipeptidyl peptidase IV (DPP-4) inhibitors. These compounds display excellent oral bioavailability and good overall phar

AMINOCYCLOHEXANES AS DIPEPTIDYL PEPTIDASE-IV INHIBITORS FOR THE TREATMENT OR PREVENTION OF DIABETES

The present invention is directed to novel substituted aminocyclohexanes which are inhibitors of the dipeptidyl peptidase-IV enzyme ("DPP-IV inhibitors") and which are useful in the treatment or prevention of diseases in which the dipeptidyl peptidase-IV enzyme is involved, such as diabetes and particularly Type 2 diabetes. The invention is also directed to pharmaceutical compositions comprising these compounds and the use of these compounds and compositions in the prevention or treatment of such diseases in which the dipeptidyl peptidase-IV enzyme is involved.